United Therapeutics Corporation (NASDAQ:UTHR) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 27.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 246,359 shares of the biotechnology company's stock after purchasing an additional 52,951 shares during the quarter. Victory Capital Management Inc. owned approximately 0.55% of United Therapeutics worth $75,945,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in UTHR. Dunhill Financial LLC boosted its stake in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares during the period. Sound Income Strategies LLC bought a new position in shares of United Therapeutics during the 1st quarter worth approximately $49,000. State of Wyoming acquired a new stake in United Therapeutics in the 4th quarter worth about $62,000. Curat Global LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $63,000. Finally, Millstone Evans Group LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $67,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Down 0.3%

Shares of United Therapeutics stock opened at $297.33 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The company has a market capitalization of $13.41 billion, a PE ratio of 11.86, a PEG ratio of 6.52 and a beta of 0.53. The stock's fifty day simple moving average is $300.61 and its 200 day simple moving average is $318.55.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. United Therapeutics's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the firm earned $6.17 EPS. Analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Raymond Dwek sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $285.57, for a total transaction of $856,710.00. Following the transaction, the director owned 1,750 shares in the company, valued at approximately $499,747.50. This trade represents a 63.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,681 shares of company stock worth $22,140,089. 10.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on UTHR. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Bank of America decreased their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Morgan Stanley decreased their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.